UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment

British journal of cancer, 2016-12, Vol.115 (12), p.1504-1512

2016

Volltextzugriff (PDF)

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression

PloS one, 2017-08, Vol.12 (8), p.e0182885-e0182885

2017

Volltextzugriff (PDF)

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation

Annals of oncology, 2012-12, Vol.23 (12), p.3188-3189

2012

Volltextzugriff (PDF)

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

British journal of cancer, 2014-07, Vol.111 (2), p.413-420

2014

Volltextzugriff (PDF)

Lung Cysts as Indicator for Birt–Hogg–Dubé Syndrome

Lung, 2014-02, Vol.192 (1), p.215-216

2014

Volltextzugriff (PDF)

Guidance for laboratories performing molecular pathology for cancer patients

Journal of clinical pathology, 2014-11, Vol.67 (11), p.923-931

2014

Volltextzugriff (PDF)

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

Lung cancer (Amsterdam, Netherlands), 2012-04, Vol.76 (1), p.1-18

2012

Volltextzugriff (PDF)

Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort

The European respiratory journal, 2012-07, Vol.40 (1), p.177-184

2012

Volltextzugriff (PDF)

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment

European journal of cancer (1990), 2011-11, Vol.47 (17), p.2603-2606

2011

Volltextzugriff (PDF)

Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome

Clinical cancer research, 2018-01, Vol.24 (1), p.33-42

2018

Volltextzugriff (PDF)

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging

Annals of oncology, 2011-03, Vol.22 (3), p.559-566

2011

Volltextzugriff (PDF)

Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity

The Journal of clinical investigation, 2021-03, Vol.131 (6), p.1-16

2021

Volltextzugriff (PDF)

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Archives of pathology & laboratory medicine (1976), 2018-03, Vol.142 (3), p.321-346

2018

Volltextzugriff (PDF)

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients

British journal of cancer, 2009-01, Vol.100 (1), p.145-152

2009

Volltextzugriff (PDF)

Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status

Clinical cancer research, 2013, Vol.19 (1), p.183-193

2013

Volltextzugriff (PDF)

Crystal Structure of MltA from Escherichia coli Reveals a Unique Lytic Transglycosylase Fold

Journal of molecular biology, 2005-10, Vol.352 (5), p.1068-1080

2005

Volltextzugriff (PDF)

A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2010-06, Vol.16 (11), p.3078-3087

2010

Volltextzugriff (PDF)

Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis

Lung cancer (Amsterdam, Netherlands), 2015-09, Vol.89 (3), p.255-261

2015

Volltextzugriff (PDF)

A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations

Cellular oncology : the official journal of the International Society for Cellular Oncology, 2009, Vol.31 (3), p.161-167

2009

Volltextzugriff (PDF)

Is the current diagnostic algorithm reliable for selecting cases for EGFR - and KRAS -mutation analysis in lung cancer?

Lung cancer (Amsterdam, Netherlands), 2015-07, Vol.89 (1), p.19-26

2015

Volltextzugriff (PDF)

Purification, crystallization and preliminary X-ray analysis of the lytic transglycosylase MltA from Escherichia coli

Acta crystallographica. Section D, Biological crystallography., 2004-04, Vol.60 (4), p.758-760

2004

Volltextzugriff (PDF)

Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?

Familial cancer, 2016-04, Vol.15 (2), p.297-300

2016

Volltextzugriff (PDF)

Detecting resistance in

Personalized medicine, 2015-03, Vol.12 (2), p.63-66

2015

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

ThemaMutation

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(25)
Humans
(22)
Oncology
(16)
Lung Neoplasms - Genetics
(14)
Female
(12)
Male
(12)
Adult
(11)
Carcinoma, Non-Small-Cell Lung - Genetics
(10)
Lung Neoplasms - Drug Therapy
(10)
Biological And Medical Sciences
(9)
Lung Cancer
(9)
Middle Aged
(9)
Pathology
(9)
Aged
(8)
Medical Sciences
(8)
Receptor, Epidermal Growth Factor - Genetics
(8)
Antineoplastic Agents - Therapeutic Use
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(6)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project

Lung Cysts as Indicator for Birt–Hogg–Dubé Syndrome

Guidance for laboratories performing molecular pathology for cancer patients

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment

Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging

Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients

Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status

Crystal Structure of MltA from Escherichia coli Reveals a Unique Lytic Transglycosylase Fold

A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non-Small Cell Lung Cancer

Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis

A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations

Is the current diagnostic algorithm reliable for selecting cases for EGFR - and KRAS -mutation analysis in lung cancer?

Purification, crystallization and preliminary X-ray analysis of the lytic transglycosylase MltA from Escherichia coli

Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?

Detecting resistance in

Aktive Filter

Suchergebnisse filtern